Barclays lowered the firm’s price target on LivaNova (LIVN) to $55 from $56 and keeps an Equal Weight rating on the shares. The company reported a “robust beat” and its sales guidance was raised, the analyst tells investors in a research note. The firm says LivaNova’s Cardio and Epilepsy are on track for a solid 2025 performance.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue